Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

Paul Statkevich, Teddy Kosoglou, Richard A Preston, Bharath Kumar, Fengjuan Xuan, Craig Trusley, James E. Schiller, Ronald B. Langdon, David L. Cutler

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Purpose: To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite. Methods: This was an open-label study in which a single 40-mg oral dose of vorapaxar was administered to patients with mild (n=6), moderate (n=6), and severe (n=4) hepatic impairment and healthy controls (n=16) matched for age, gender, weight, and height. Blood samples for vorapaxar and M20 assay were collected predose and at frequent intervals up to 8 weeks postdose. Results: Plasma vorapaxar and M20 PK profiles were similar between patients with impaired liver function and healthy controls. Group mean values for vorapaxar C max and AUCtf were 206-279 ng/mL and 14,200-18,200 ng·h/mL, respectively, with the lowest values observed in patients with severe impairment. Vorapaxar median Tmax and mean t1/2 values were 1.00-1.75 h and 298-366 h, respectively. There was no apparent correlation between vorapaxar or M20 exposure or t1/2 values and disease severity. Vorapaxar was generally well tolerated; one serious adverse event (gastrointestinal bleeding secondary to ruptured esophageal varices) was reported in a patient with severe hepatic impairment. Conclusions: Hepatic impairment had no clinically relevant effect on the PK of vorapaxar and M20. No dose or dosage adjustment of vorapaxar will be required in patients with mild to moderate hepatic impairment. Although systemic exposure to vorapaxar does not appear to increase in patients with severe hepatic impairment, administration of vorapaxar to such patients is not recommended given their bleeding diathesis.

Original languageEnglish
Pages (from-to)1501-1508
Number of pages8
JournalEuropean Journal of Clinical Pharmacology
Volume68
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Pharmacokinetics
Liver
vorapaxar
Hemorrhage
Esophageal and Gastric Varices
Disease Susceptibility
Weights and Measures

Keywords

  • Hepatic impairment
  • PAR-1 antagonist
  • Pharmacokinetics
  • SCH 530348
  • Thrombin receptor antagonist
  • Vorapaxar

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. / Statkevich, Paul; Kosoglou, Teddy; Preston, Richard A; Kumar, Bharath; Xuan, Fengjuan; Trusley, Craig; Schiller, James E.; Langdon, Ronald B.; Cutler, David L.

In: European Journal of Clinical Pharmacology, Vol. 68, No. 11, 01.11.2012, p. 1501-1508.

Research output: Contribution to journalArticle

Statkevich, P, Kosoglou, T, Preston, RA, Kumar, B, Xuan, F, Trusley, C, Schiller, JE, Langdon, RB & Cutler, DL 2012, 'Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment', European Journal of Clinical Pharmacology, vol. 68, no. 11, pp. 1501-1508. https://doi.org/10.1007/s00228-012-1269-7
Statkevich, Paul ; Kosoglou, Teddy ; Preston, Richard A ; Kumar, Bharath ; Xuan, Fengjuan ; Trusley, Craig ; Schiller, James E. ; Langdon, Ronald B. ; Cutler, David L. / Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment. In: European Journal of Clinical Pharmacology. 2012 ; Vol. 68, No. 11. pp. 1501-1508.
@article{a5b09ba399794b329ea55fa8f8d4a6e2,
title = "Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment",
abstract = "Purpose: To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite. Methods: This was an open-label study in which a single 40-mg oral dose of vorapaxar was administered to patients with mild (n=6), moderate (n=6), and severe (n=4) hepatic impairment and healthy controls (n=16) matched for age, gender, weight, and height. Blood samples for vorapaxar and M20 assay were collected predose and at frequent intervals up to 8 weeks postdose. Results: Plasma vorapaxar and M20 PK profiles were similar between patients with impaired liver function and healthy controls. Group mean values for vorapaxar C max and AUCtf were 206-279 ng/mL and 14,200-18,200 ng·h/mL, respectively, with the lowest values observed in patients with severe impairment. Vorapaxar median Tmax and mean t1/2 values were 1.00-1.75 h and 298-366 h, respectively. There was no apparent correlation between vorapaxar or M20 exposure or t1/2 values and disease severity. Vorapaxar was generally well tolerated; one serious adverse event (gastrointestinal bleeding secondary to ruptured esophageal varices) was reported in a patient with severe hepatic impairment. Conclusions: Hepatic impairment had no clinically relevant effect on the PK of vorapaxar and M20. No dose or dosage adjustment of vorapaxar will be required in patients with mild to moderate hepatic impairment. Although systemic exposure to vorapaxar does not appear to increase in patients with severe hepatic impairment, administration of vorapaxar to such patients is not recommended given their bleeding diathesis.",
keywords = "Hepatic impairment, PAR-1 antagonist, Pharmacokinetics, SCH 530348, Thrombin receptor antagonist, Vorapaxar",
author = "Paul Statkevich and Teddy Kosoglou and Preston, {Richard A} and Bharath Kumar and Fengjuan Xuan and Craig Trusley and Schiller, {James E.} and Langdon, {Ronald B.} and Cutler, {David L.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1007/s00228-012-1269-7",
language = "English",
volume = "68",
pages = "1501--1508",
journal = "European Journal of Clinical Pharmacology",
issn = "0031-6970",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment

AU - Statkevich, Paul

AU - Kosoglou, Teddy

AU - Preston, Richard A

AU - Kumar, Bharath

AU - Xuan, Fengjuan

AU - Trusley, Craig

AU - Schiller, James E.

AU - Langdon, Ronald B.

AU - Cutler, David L.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Purpose: To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite. Methods: This was an open-label study in which a single 40-mg oral dose of vorapaxar was administered to patients with mild (n=6), moderate (n=6), and severe (n=4) hepatic impairment and healthy controls (n=16) matched for age, gender, weight, and height. Blood samples for vorapaxar and M20 assay were collected predose and at frequent intervals up to 8 weeks postdose. Results: Plasma vorapaxar and M20 PK profiles were similar between patients with impaired liver function and healthy controls. Group mean values for vorapaxar C max and AUCtf were 206-279 ng/mL and 14,200-18,200 ng·h/mL, respectively, with the lowest values observed in patients with severe impairment. Vorapaxar median Tmax and mean t1/2 values were 1.00-1.75 h and 298-366 h, respectively. There was no apparent correlation between vorapaxar or M20 exposure or t1/2 values and disease severity. Vorapaxar was generally well tolerated; one serious adverse event (gastrointestinal bleeding secondary to ruptured esophageal varices) was reported in a patient with severe hepatic impairment. Conclusions: Hepatic impairment had no clinically relevant effect on the PK of vorapaxar and M20. No dose or dosage adjustment of vorapaxar will be required in patients with mild to moderate hepatic impairment. Although systemic exposure to vorapaxar does not appear to increase in patients with severe hepatic impairment, administration of vorapaxar to such patients is not recommended given their bleeding diathesis.

AB - Purpose: To determine whether hepatic impairment has an effect on the pharmacokinetics (PK) of vorapaxar or M20, its main pharmacologically active metabolite. Methods: This was an open-label study in which a single 40-mg oral dose of vorapaxar was administered to patients with mild (n=6), moderate (n=6), and severe (n=4) hepatic impairment and healthy controls (n=16) matched for age, gender, weight, and height. Blood samples for vorapaxar and M20 assay were collected predose and at frequent intervals up to 8 weeks postdose. Results: Plasma vorapaxar and M20 PK profiles were similar between patients with impaired liver function and healthy controls. Group mean values for vorapaxar C max and AUCtf were 206-279 ng/mL and 14,200-18,200 ng·h/mL, respectively, with the lowest values observed in patients with severe impairment. Vorapaxar median Tmax and mean t1/2 values were 1.00-1.75 h and 298-366 h, respectively. There was no apparent correlation between vorapaxar or M20 exposure or t1/2 values and disease severity. Vorapaxar was generally well tolerated; one serious adverse event (gastrointestinal bleeding secondary to ruptured esophageal varices) was reported in a patient with severe hepatic impairment. Conclusions: Hepatic impairment had no clinically relevant effect on the PK of vorapaxar and M20. No dose or dosage adjustment of vorapaxar will be required in patients with mild to moderate hepatic impairment. Although systemic exposure to vorapaxar does not appear to increase in patients with severe hepatic impairment, administration of vorapaxar to such patients is not recommended given their bleeding diathesis.

KW - Hepatic impairment

KW - PAR-1 antagonist

KW - Pharmacokinetics

KW - SCH 530348

KW - Thrombin receptor antagonist

KW - Vorapaxar

UR - http://www.scopus.com/inward/record.url?scp=84867573817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867573817&partnerID=8YFLogxK

U2 - 10.1007/s00228-012-1269-7

DO - 10.1007/s00228-012-1269-7

M3 - Article

C2 - 22527342

AN - SCOPUS:84867573817

VL - 68

SP - 1501

EP - 1508

JO - European Journal of Clinical Pharmacology

JF - European Journal of Clinical Pharmacology

SN - 0031-6970

IS - 11

ER -